Veloxis Pharmaceuticals

Veloxis Pharmaceuticals

Market Cap:
$256.2 million
Revenue:
$2 million
Net Income:
$-27.2 million

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. Wikipedia

Veloxis Pharmaceuticals

Market Cap:
$256.2 million
Revenue:
$2 million
Net Income:
$-27.2 million

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. Wikipedia